1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. New York >
  6. Nuvation Bio Acquires AnHeart

M&A Deal Summary

Nuvation Bio Acquires AnHeart

On March 25, 2024, Nuvation Bio acquired life science company AnHeart

Acquisition Highlights
  • This is Nuvation Bio’s 1st transaction in the Life Science sector.
  • This is Nuvation Bio’s 1st transaction in the United States.
  • This is Nuvation Bio’s 1st transaction in New York.

M&A Deal Summary
Date 2024-03-25
Target AnHeart
Sector Life Science
Buyer(s) Nuvation Bio
Deal Type Add-on Acquisition
Advisor(s) Davis Polk & Wardwell
Fangda Partners
Walkers Global (Legal)

Target

AnHeart

New York, New York, United States
AnHeart is a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. AnHeart’s lead investigational therapy, taletrectinib, is a next-generation ROS1 inhibitor currently in pivotal Phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart is based in New York, New York.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Nuvation Bio

New York, New York, United States
Category Company
Founded 2018
Sector Life Science
Employees273
Revenue 8M USD (2024)
DESCRIPTION

Nuvation Bio is an oncology drug development company pursuing first-in-class and best-in-class anti-cancer agents. Nuvation Bio was founded in 2018 and is based in New York, New York.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: New York M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2024 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal